Clinical Trial Update: A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating 24- or 48-week telaprevir-based regimens in treatment-naïve genotype 1 Hepatitis C patients achieving extended rapid virologic response…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Telaprevir (telaprevir)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2011-07-21